GALAPAGOS NV (GLPG.AS) Stock Price, Forecast & Analysis
Europe - Euronext Amsterdam - AMS:GLPG - BE0003818359 - Common Stock
GLPG.AS Key Statistics, Chart & Performance
The current stock price of GLPG.AS is 26.72 EUR. In the past month the price decreased by -1.55%. In the past year, price increased by 1.75%.
GLPG.AS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 74.26 | 49.11B | ||
| ARGX.BR | ARGENX SE | 73.63 | 48.69B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.12B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.70B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.64B | ||
| 5CV.DE | CUREVAC NV | 5.36 | 1.05B | ||
| NANO.PA | NANOBIOTIX | N/A | 845.70M | ||
| PHIL.MI | PHILOGEN SPA | 21.05 | 701.76M | ||
| IVA.PA | INVENTIVA SA | N/A | 546.97M | ||
| ALCLS.PA | CELLECTIS | N/A | 445.95M | ||
| FYB.DE | FORMYCON AG | N/A | 434.68M | ||
| VLA.PA | VALNEVA SE | N/A | 369.44M |
Related stock screener links
About GLPG.AS
Company Profile
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 558 full-time employees. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Company Info
GALAPAGOS NV
Generaal De Wittelaan L11 A3
MALINES (MECHELEN) ANTWERPEN BE
Employees: 704
Phone: 3215342900
GALAPAGOS NV / GLPG.AS FAQ
What does GLPG do?
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 558 full-time employees. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
What is the stock price of GALAPAGOS NV today?
The current stock price of GLPG.AS is 26.72 EUR. The price increased by 0.3% in the last trading session.
Does GLPG stock pay dividends?
GLPG.AS does not pay a dividend.
How is the ChartMill rating for GALAPAGOS NV?
GLPG.AS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting GLPG stock to perform?
17 analysts have analysed GLPG.AS and the average price target is 29.75 EUR. This implies a price increase of 11.32% is expected in the next year compared to the current price of 26.72.
How many employees does GALAPAGOS NV have?
GALAPAGOS NV (GLPG.AS) currently has 704 employees.
What is the market capitalization of GLPG stock?
GALAPAGOS NV (GLPG.AS) has a market capitalization of 1.76B EUR. This makes GLPG.AS a Small Cap stock.
GLPG.AS Technical Analysis
GLPG.AS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GLPG.AS. While GLPG.AS seems to be doing ok healthwise, there are quite some concerns on its profitability.
GLPG.AS Financial Highlights
Over the last trailing twelve months GLPG.AS reported a non-GAAP Earnings per Share(EPS) of -6.62. The EPS decreased by -311.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.41% | ||
| ROE | -17.82% | ||
| Debt/Equity | 0 |
GLPG.AS Forecast & Estimates
17 analysts have analysed GLPG.AS and the average price target is 29.75 EUR. This implies a price increase of 11.32% is expected in the next year compared to the current price of 26.72.
For the next year, analysts expect an EPS growth of -346.2% and a revenue growth -5.39% for GLPG.AS